Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis
Pyrazinamide (PZA) is a frontline anti-tuberculosis drug that plays a crucial role in the treatment of both drug-susceptible and multidrug-resistant tuberculosis (MDR-TB). PZA is a prodrug that is converted to its active form, pyrazinoic acid (POA), by a nicotinamidase/pyrazinamidase encoded by the...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2014-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1038/emi.2014.61 |
| _version_ | 1797679817527656448 |
|---|---|
| author | Wanliang Shi Jiazhen Chen Jie Feng Peng Cui Shuo Zhang Xinhua Weng Wenhong Zhang Ying Zhang |
| author_facet | Wanliang Shi Jiazhen Chen Jie Feng Peng Cui Shuo Zhang Xinhua Weng Wenhong Zhang Ying Zhang |
| author_sort | Wanliang Shi |
| collection | DOAJ |
| description | Pyrazinamide (PZA) is a frontline anti-tuberculosis drug that plays a crucial role in the treatment of both drug-susceptible and multidrug-resistant tuberculosis (MDR-TB). PZA is a prodrug that is converted to its active form, pyrazinoic acid (POA), by a nicotinamidase/pyrazinamidase encoded by the pncA gene, the mutation of which is the major cause of PZA resistance. Although RpsA (ribosomal protein S1, involved in trans-translation) has recently been shown to be a target of POA/PZA, whole-genome sequencing has identified mutations in the panD gene encoding aspartate decarboxylase in PZA-resistant strains lacking pncA and rpsA mutations. To gain more insight into a possible new target of PZA, we isolated 30 POA-resistant mutants lacking mutations in pncA and rpsA from M. tuberculosis in vitro, and whole-genome sequencing of 3 mutants identified various mutations in the panD gene. Additionally, sequencing analysis revealed that the remaining 27 POA-resistant mutants all harbored panD mutations affecting the C-terminus of the PanD protein, with PanD M117I being the most frequent mutation (24/30, 80%). Conditional overexpression of panD from M. tuberculosis, M. smegmatis or E. coli, or of M. tuberculosis mutant PanD M117I, all conferred resistance to POA and PZA in M. tuberculosis. β-alanine and pantothenate, which are downstream products of PanD, were found to antagonize the antituberculosis activity of POA. In addition, the activity of the M. tuberculosis PanD enzyme was inhibited by POA at therapeutically relevant concentrations in a concentration-dependent manner but was not inhibited by the prodrug PZA or the control compound nicotinamide. These findings suggest that PanD represents a new target of PZA/POA. These results have implications for a better understanding of this peculiar persister drug and for the design of new drugs targeting M. tuberculosis persisters for improved treatment. |
| first_indexed | 2024-03-11T23:20:24Z |
| format | Article |
| id | doaj.art-4bc8e675bd574fa797589cb7d4d988a3 |
| institution | Directory Open Access Journal |
| issn | 2222-1751 |
| language | English |
| last_indexed | 2024-03-11T23:20:24Z |
| publishDate | 2014-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj.art-4bc8e675bd574fa797589cb7d4d988a32023-09-20T14:20:33ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512014-01-01311810.1038/emi.2014.61Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosisWanliang Shi0Jiazhen Chen1Jie Feng2Peng Cui3Shuo Zhang4Xinhua Weng5Wenhong Zhang6Ying Zhang7Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USADepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, ChinaDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USADepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, ChinaDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USADepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, ChinaDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai 200040, ChinaDepartment of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USAPyrazinamide (PZA) is a frontline anti-tuberculosis drug that plays a crucial role in the treatment of both drug-susceptible and multidrug-resistant tuberculosis (MDR-TB). PZA is a prodrug that is converted to its active form, pyrazinoic acid (POA), by a nicotinamidase/pyrazinamidase encoded by the pncA gene, the mutation of which is the major cause of PZA resistance. Although RpsA (ribosomal protein S1, involved in trans-translation) has recently been shown to be a target of POA/PZA, whole-genome sequencing has identified mutations in the panD gene encoding aspartate decarboxylase in PZA-resistant strains lacking pncA and rpsA mutations. To gain more insight into a possible new target of PZA, we isolated 30 POA-resistant mutants lacking mutations in pncA and rpsA from M. tuberculosis in vitro, and whole-genome sequencing of 3 mutants identified various mutations in the panD gene. Additionally, sequencing analysis revealed that the remaining 27 POA-resistant mutants all harbored panD mutations affecting the C-terminus of the PanD protein, with PanD M117I being the most frequent mutation (24/30, 80%). Conditional overexpression of panD from M. tuberculosis, M. smegmatis or E. coli, or of M. tuberculosis mutant PanD M117I, all conferred resistance to POA and PZA in M. tuberculosis. β-alanine and pantothenate, which are downstream products of PanD, were found to antagonize the antituberculosis activity of POA. In addition, the activity of the M. tuberculosis PanD enzyme was inhibited by POA at therapeutically relevant concentrations in a concentration-dependent manner but was not inhibited by the prodrug PZA or the control compound nicotinamide. These findings suggest that PanD represents a new target of PZA/POA. These results have implications for a better understanding of this peculiar persister drug and for the design of new drugs targeting M. tuberculosis persisters for improved treatment.https://www.tandfonline.com/doi/10.1038/emi.2014.61Pyrazinamidepyrazinoic acid resistancemode of actionpanDaspartate decarboxylase |
| spellingShingle | Wanliang Shi Jiazhen Chen Jie Feng Peng Cui Shuo Zhang Xinhua Weng Wenhong Zhang Ying Zhang Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis Emerging Microbes and Infections Pyrazinamide pyrazinoic acid resistance mode of action panD aspartate decarboxylase |
| title | Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis |
| title_full | Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis |
| title_fullStr | Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis |
| title_full_unstemmed | Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis |
| title_short | Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis |
| title_sort | aspartate decarboxylase pand as a new target of pyrazinamide in mycobacterium tuberculosis |
| topic | Pyrazinamide pyrazinoic acid resistance mode of action panD aspartate decarboxylase |
| url | https://www.tandfonline.com/doi/10.1038/emi.2014.61 |
| work_keys_str_mv | AT wanliangshi aspartatedecarboxylasepandasanewtargetofpyrazinamideinmycobacteriumtuberculosis AT jiazhenchen aspartatedecarboxylasepandasanewtargetofpyrazinamideinmycobacteriumtuberculosis AT jiefeng aspartatedecarboxylasepandasanewtargetofpyrazinamideinmycobacteriumtuberculosis AT pengcui aspartatedecarboxylasepandasanewtargetofpyrazinamideinmycobacteriumtuberculosis AT shuozhang aspartatedecarboxylasepandasanewtargetofpyrazinamideinmycobacteriumtuberculosis AT xinhuaweng aspartatedecarboxylasepandasanewtargetofpyrazinamideinmycobacteriumtuberculosis AT wenhongzhang aspartatedecarboxylasepandasanewtargetofpyrazinamideinmycobacteriumtuberculosis AT yingzhang aspartatedecarboxylasepandasanewtargetofpyrazinamideinmycobacteriumtuberculosis |